Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

Abstract The clinical safety and efficacy of IPI-926 was evaluated in 14 patients with myelofibrosis in a phase II study. Patients received 160 mg IPI-926 orally in continuous 28-day cycles. The median treatment duration was 5.1 months, and all patients had discontinued treatment by 7.5 months. Nine patients discontinued due to lack of response as determined by the treating physician, two after developing acute leukemia and one due to disease progression/loss of response. Twelve patients had slight reductions in spleen size (less than 50% from baseline), but symptoms did not improve consistently. One patient achieved transfusion independence lasting 5 months. Reductions in GLI1 mRNA and protein levels, JAK2V617F allele burden, degree of fibrosis or cytokine levels were observed in some patients, but were not significant when evaluated for the cohort. Low-grade gastrointestinal/liver abnormalities were the most common toxicities. The results did not support continued evaluation of IPI-926 as a monotherapy in myelofibrosis.

[1]  Hongwei Wang,et al.  Epidemiology of myeloproliferative neoplasms in the United States , 2014, Leukemia & lymphoma.

[2]  T. Barbui,et al.  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. , 2013, Blood.

[3]  J. Dipersio,et al.  Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I , 2013, Haematologica.

[4]  J. Dipersio,et al.  Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I , 2013, Haematologica.

[5]  E. Stanchina,et al.  Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis , 2013 .

[6]  D. McCoy,et al.  Platelet-derived growth factor-A and sonic hedgehog signaling direct lung fibroblast precursors during alveolar septal formation. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[7]  R. Badolato,et al.  The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse. , 2013, Blood.

[8]  C. Rudin,et al.  Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors , 2013, Clinical Cancer Research.

[9]  M. Cazzola,et al.  Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. , 2012, Blood.

[10]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[11]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[12]  M. Baccarani,et al.  Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies , 2011 .

[13]  T. Barbui,et al.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. , 2011, Blood.

[14]  M. Griesshammer,et al.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Tallman,et al.  Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. , 2010, Blood.

[16]  M. Scott,et al.  The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins. , 2010, Genes & development.

[17]  H. Kantarjian,et al.  Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[19]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[20]  P. Fenaux,et al.  Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms , 2008, Leukemia.

[21]  L. Greenbaum Hedgehog signaling in biliary fibrosis. , 2008, The Journal of clinical investigation.

[22]  N. Shinton WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[23]  Francisco Cervantes,et al.  Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). , 2007, Leukemia research.

[24]  H. Deeg,et al.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.

[25]  R. Mesa,et al.  Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic , 2006, Cancer.

[26]  H. Kantarjian,et al.  Thalidomide therapy for myelofibrosis with myeloid metaplasia , 2006, Cancer.

[27]  Marina Pasca di Magliano,et al.  Hedgehog signalling in cancer formation and maintenance , 2003, Nature Reviews Cancer.

[28]  Jussi Taipale,et al.  Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. , 2002, Genes & development.

[29]  P. Sánchez,et al.  Gli and hedgehog in cancer: tumours, embryos and stem cells , 2002, Nature Reviews Cancer.

[30]  P. Mouton,et al.  Length measurement: new developments in neurostereology and 3D imagery , 2000, Journal of Chemical Neuroanatomy.

[31]  M. Scott,et al.  Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine , 2000, Nature.

[32]  A. Tefferi Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[33]  T. Taguchi,et al.  [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[34]  A. Manoharan,et al.  MANAGEMENT OF MYELOFIBROSIS WITH INTERMITTENT HYDROXYUREA , 1991, British journal of haematology.

[35]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[36]  O. M. Ávila-Cabrera,et al.  BCR-ABL negative myeloproliferative neoplasms , 2013 .

[37]  J. D. van der Walt,et al.  European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.